Thanks Citrati... for anyone who reads it, the information is very positive... the market will take a bump downward because it appears there still is some time to go one what is most important to investors right now.... The covid trials.
But if you read it and go all the way to the end you will see this paragraph, and up until now they have not done a good job of explaining what SOC, Standard of Care is. He does explain it here and it really says it all. In the long run this is going to be a very very financially successful drug and company to be invested in.
Mike Macaluso -- Chairman and Chief Executive Officer said the following in his closing.
And also I'd like to stress this point that we use the word standard of care like it's a placebo of sugar water or something. The standard of care is FDA-approved drugs and -- or drugs approved by the FDA for emergency use. And we've been better. We've been better. (If Ampion is out performing drugs already on the market, there is little chance they will not be approved in the end. Approval means dollars added to the PPS of the stock... many many dollars.)
The hospitals suggest that. Our results suggest that. And the comparison -- comparative analysis, Holli shared with you suggested that. So we're optimistic about the use of this drug, COVID or not related.
And it's important that we're running these trials in a way so that there is some transfer of what we're learning to other indications and other diseases. We're managing our cash carefully, and that's important. We're not raising money, that's important. So I think we're in really good shape now.
And I'm glad, again, we had to put OAK to bed, and we've done that. And we now have to concentrate on these other trials and not to stop the research that David is doing on these other indications. Because as we have these partnering talks and we talk about a platform technology, I think it's important that we can show data, clinical data, trials, research information to support that comment with our manufacturing. So that's it.
